Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Primary Purpose
HCV Recurrence After Liver Transplantation
Status
Terminated
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Silibinin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for HCV Recurrence After Liver Transplantation focused on measuring HCV recurrence, HCV reinfection, Liver transplantation, Legalon SIL, silibinin, viral load
Eligibility Criteria
Inclusion Criteria:
- Patient must provide signed and dated informed consent before undergoing any trial related procedure.
- Patient between 18 and 70 years of age.
- Patient must have documented HCV infection. The HCV-RNA result obtained from the local laboratory at the screening visit must confirm HCV-RNA > 1000 IU/mL.
- Patient must qualify for liver transplantation at the time of Screening according to Model for End stage Liver Disease (MELD) criteria
- Patient must have a documented diagnosis of cirrhosis.
- Patient weigh between 50 kg and 100 kg.
- Patients must be able to communicate, participate and comply with the requirements of the entire study.
- Female patients of child-bearing potential must agree on using a contraceptive method (oral contraceptive, intrauterine device, transdermal contraceptive patch) and must have a negative pregnancy urine test at screening.
- HCV Genotype, chest X-ray, ultrasonography and ocular examination (for patients with history of diabetes or hypertension) must be performed within 6 months prior to Screening or between Screening and Day 1. 12-Lead ECG must be performed within 3 months prior to Screening.
Exclusion Criteria:
- Patients known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).
- Active septic infections at time of screening.
- Previous organ transplantation other than cornea and hair.
- Use of systemic immunosuppressant or immunomodulating agents (including systemic corticosteroids) within 4 weeks of the screening visit or during the screening period.
- Treatment for HCV with any investigational medication (prior use of silymarin is not exclusionary)
- Treatment for HCV with any licensed therapies or prior maintenance therapy with any interferon alpha within 30 days of the randomization visit.
- Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study.
Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study including but not limited to:
- Chronic pulmonary disease (eg, clinical chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis).
- Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension, or history of use of antianginal agents for cardiac conditions.
- Any other condition which, in the opinion of a physician-investigator, would make the patient unsuitable for enrollment or could interfere with the subject participating in and completing the study.
- Subjects who are part of the site personnel directly involved with this study or those who are family members of the investigational study staff.
- If female, pregnancy or breast-feeding.
- Known hypersensitivity to Legalon® SIL.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
silibinin
Placebo
Arm Description
Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
Outcomes
Primary Outcome Measures
Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant
Secondary Outcome Measures
Virologic response (VR) defined as undetectable HCV RNA
Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA
Number of patients with AE
laboratory parameters
blood levels of immunosuppressive drugs
Vital signs
ECG
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01535092
Brief Title
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Official Title
A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Terminated
Why Stopped
when realized that the target 60% of patients with SVR was no more achievable
Study Start Date
September 2010 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rottapharm
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Orthotopic liver transplantation (OLT) is the treatment of choice for patients with Hepatitis C Virus (HCV) infection and end-stage liver disease or hepatocellular carcinoma; infection of the graft and hepatitis C recurrence is universal after OLT and recurrent HCV hepatitis often follows an accelerated course after OLT, with rapid histological recurrence and cirrhosis. These very poor outcome significantly affect graft and patient survival and reduces the benefit of transplantation for this indication. Therapeutic strategies are not available; high viral load, high prevalence of genotype 1b and need of dose reduction of interferon and ribavirin because of the side effects or intolerance, together with the interference of immunosuppressive drugs, resulted in the vast majority of the patients in failure in obtaining viral eradication.
Recently, Silibinin, has been studied and reported to be capable to act as potent antiviral agent in patients with HCV; it has been used successfully in a protocol of a 14 day intravenous infusion in previous non-responders to peginterferon/ribavirin therapy. In view of his postulated profile of safety, it seems an ideal drug to be used in the setting of HCV recurrent patients after liver transplant.
Aim of this prospective, randomized, double-blind, placebo-controlled, parallel group study is to determine the therapeutic effect of Legalon SIL in the prevention of HCV reinfection in chronically infected hepatitis C patients after OLT.
Awaiting orthotopic liver transplantation patients affected by HCV will be randomised 3:1 to receive, in addition to their current therapy, silibinin 20mg/kg/day (Legalon SIL) or placebo infused over 2 hours from 14 to 21 consecutive days; in addition, patients will receive treatment with silibinin 20mg/kg/day (Legalon SIL), infused over 2 hours, for 7 days after transplant.
The Primary Efficacy endpoint is to achieve sustained virological response (SVR) while Secondary Efficacy endpoints are to evaluate the virologic response, the percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA and the safety of Legalon SIL in this population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HCV Recurrence After Liver Transplantation
Keywords
HCV recurrence, HCV reinfection, Liver transplantation, Legalon SIL, silibinin, viral load
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
silibinin
Arm Type
Experimental
Arm Description
Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
Intervention Type
Drug
Intervention Name(s)
Silibinin
Other Intervention Name(s)
Legalon SIL
Intervention Description
20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
Primary Outcome Measure Information:
Title
Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Virologic response (VR) defined as undetectable HCV RNA
Time Frame
after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
Title
Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA
Time Frame
at week 4 after OLT
Title
Number of patients with AE
Time Frame
after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
Title
laboratory parameters
Time Frame
after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
Title
blood levels of immunosuppressive drugs
Time Frame
week 1, 2, 3, 4, 8, 12, 24 after OLT
Title
Vital signs
Time Frame
after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
Title
ECG
Time Frame
after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient must provide signed and dated informed consent before undergoing any trial related procedure.
Patient between 18 and 70 years of age.
Patient must have documented HCV infection. The HCV-RNA result obtained from the local laboratory at the screening visit must confirm HCV-RNA > 1000 IU/mL.
Patient must qualify for liver transplantation at the time of Screening according to Model for End stage Liver Disease (MELD) criteria
Patient must have a documented diagnosis of cirrhosis.
Patient weigh between 50 kg and 100 kg.
Patients must be able to communicate, participate and comply with the requirements of the entire study.
Female patients of child-bearing potential must agree on using a contraceptive method (oral contraceptive, intrauterine device, transdermal contraceptive patch) and must have a negative pregnancy urine test at screening.
HCV Genotype, chest X-ray, ultrasonography and ocular examination (for patients with history of diabetes or hypertension) must be performed within 6 months prior to Screening or between Screening and Day 1. 12-Lead ECG must be performed within 3 months prior to Screening.
Exclusion Criteria:
Patients known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).
Active septic infections at time of screening.
Previous organ transplantation other than cornea and hair.
Use of systemic immunosuppressant or immunomodulating agents (including systemic corticosteroids) within 4 weeks of the screening visit or during the screening period.
Treatment for HCV with any investigational medication (prior use of silymarin is not exclusionary)
Treatment for HCV with any licensed therapies or prior maintenance therapy with any interferon alpha within 30 days of the randomization visit.
Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study.
Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study including but not limited to:
Chronic pulmonary disease (eg, clinical chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis).
Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension, or history of use of antianginal agents for cardiac conditions.
Any other condition which, in the opinion of a physician-investigator, would make the patient unsuitable for enrollment or could interfere with the subject participating in and completing the study.
Subjects who are part of the site personnel directly involved with this study or those who are family members of the investigational study staff.
If female, pregnancy or breast-feeding.
Known hypersensitivity to Legalon® SIL.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xavier Forns, Dr
Organizational Affiliation
Hospital Clinic i Barcelona
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
We'll reach out to this number within 24 hrs